文献速递脊柱关节炎

T细胞:中轴型脊柱关节炎的下一个重大靶点?

T cells, the Next Big Target in Axial Spondyloarthritis?
PubMed 文献 · Arthritis Rheumatol · 2026-05-11

本文综述中轴型脊柱关节炎(axSpA)中不同T细胞亚群的致病机制及靶向治疗策略。文章强调经典CD8+ T细胞、CD4+ Th17细胞、Treg细胞及组织驻留记忆T细胞在疾病启动和进展中的作用,并讨论先天样T细胞通过IL-23/IL-17轴驱动炎症。文章还探讨了抗TRBV9抗体、JAK抑制及细胞因子抑制剂等治疗策略的潜力与局限。

要点

  • 经典CD8+ T细胞、Th17细胞、Treg细胞及CD103+CD49a+组织驻留记忆T细胞参与axSpA启动与进展。
  • γδ T细胞、MAIT细胞、iNKT细胞及固有淋巴细胞通过IL-23依赖的IL-17产生驱动炎症和组织损伤。
  • 靶向T细胞可直接用抗TRBV9抗体或JAK抑制,或间接抑制IL-17和TNF等介质。

核心结论

  • T细胞亚群在axSpA发病机制中居核心地位,靶向T细胞或为其下游介质可能开发更有效的个体化及联合治疗。

研究设计与样本

  • 综述性文章,汇总axSpA中T细胞亚群致病机制及靶向治疗策略的现有知识。

主要发现

  • 经典αβ TCR表达的CD8+ T细胞、CD4+ Th17细胞、Treg细胞及CD103+CD49a+组织驻留记忆整合素表达T细胞参与axSpA启动和进展。
  • 先天样T细胞亚群(γδ T细胞、MAIT细胞、iNKT细胞)及固有淋巴细胞通过IL-23依赖的IL-17产生驱动炎症和组织损伤。
  • T细胞介导炎症的复杂细胞因子环境可解释部分细胞因子抑制剂疗效不佳。

临床怎么用

  • 可考虑直接靶向T细胞(抗TRBV9抗体、JAK抑制)或间接抑制IL-17和TNF等介质治疗axSpA。
  • T细胞亚群的复杂相互作用提示需开发更精准的个体化及联合治疗方案。

局限性

  • 本文为综述,未报告原始研究数据或样本量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Axial spondyloarthritis (axSpA) is a chronic inflammatory disease characterized by complex immune dysregulation, with T cells playing a central role in its pathogenesis. In this review, we synthesize current knowledge on diverse T cell subsets in axSpA, their pathogenic mechanisms, and emerging therapeutic strategies targeting these cells. We highlight conventional αβ T cell receptor-expressing CD8+ T cells, CD4+ Th17 cells and Treg cells, and CD103+CD49a+ tissue-resident memory integrin-expressing T cells in axSpA initiation and progression. Innate-like T cell subsets, including γδ T cells, mucosal-associated invariant T cells, and invariant natural killer T cells, along with innate lymphoid cells (though not T cells), contribute substantially via interlukin-17 (IL-17) production via IL-23, driving inflammation and tissue damage. We discuss a complex milieu of cytokines in T cell-mediated inflammation, offering potential explanations for inefficacy of some cytokine inhibitors. We explore alternative drivers of inflammation and their implications for developing more effective therapies targeting T cells in axSpA, either directly via anti-TRBV9 antibody therapy or JAK inhibition or indirectly by inhibiting mediators such as IL-17 and tumor necrosis factor. This complex interplay of T cell subsets in disease pathogenesis underscores the need for research to develop more targeted treatments, opening new avenues for personalized therapies and combination approaches that address multiple aspects of the inflammatory cascade in axSpA.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Aparnathi MK, Haroon N. T cells, the Next Big Target in Axial Spondyloarthritis? Arthritis Rheumatol. 2026. PMID: 42112876. doi:10.1002/art.70221

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。